IBMI

Address: 11F, 80 Linshen North Road, Taipei,Taiwan

Tel: (02)2655-8168

Web: http://www.ibmi.org.tw/client/

Company description

The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan. Supported by the President of Legislative Yuan, Mr. Wang Jin-Pyng, the predecessor of IBMI began its operation in 1998. In 1999, Mr. Wang took on the post as the chairman and defined the mission of IBMI as ‘Upgrading Biotechnology and Medicine for National Health’. In March 2002, IBMI was officially founded as an organization dedicated to promoting the biotechnology and medicine industry. In June 2005, IBMI convened its first member conference of the second year where the second board of directors and supervisors were elected. The board continued to uphold the ideology and mission of the organization to push forward industrial growth. In May 2009, at the first member conference of the third year the third board of directors and supervisors were elected. Mr. Wang Jin-Pyng was unanimously honored as the founder of IBMI and for his contribution to the biotechnology and medicine industry. Former President of National Taiwan University and the Vice Chairman of IBMI, Dr. Chen Wei-Zhao was elected as chairman of the third board of directors and supervisors to lead IBMI.

The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.

From perspective of policy development, at IBMI, it is considered that productive industry policy and market mechanism are essential for assuring the best interest of the state and the public. Innovation-based approaches to developing the emerging industry and market-oriented approaches to commercialization are keys to improving state’s economic competitiveness. Therefore, IBMI intends to assist government and industry in formulating and implementing relevant industrial policies, establishing market mechanism, fostering innovation, and ensuring global competitiveness.

Based on the above considerations, IBMI sets its priority to cause productive partnerships among academia, government, industry and research institutions. Therefore, through promotion and operation of its six functions, i.e., ‘Productive Legislation and Policies’, ‘Certification and Market Mechanism’, ‘Education and Training’, ‘Bioinformatics and Bio-trading’, ‘Advanced and Applied Bio-researches’, and ‘Emerging Business Development’, IBMI strives to develop Taiwan’s biomedical industry, improve the quality of its healthcare system, as well as enhance its overall competitiveness.

Products and services

The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan.The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.